Zhejiang Orient Gene Biotech Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
2,283
- Stock Symbol
-
688298
- Investments
-
5
- Share Price
-
$2.64
- (As of Friday Closing)
Zhejiang Orient Gene Biotech General Information
Description
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
Contact Information
Website
www.orientgene.comCorporate Office
- No. 3787 East Yangguang Avenue
- Dipu Street, Anji
- Huzhou, Zhejiang
- China
Corporate Office
- No. 3787 East Yangguang Avenue
- Dipu Street, Anji
- Huzhou, Zhejiang
- China
Zhejiang Orient Gene Biotech Stock Performance
As of 13-Nov-2026, Zhejiang Orient Gene Biotech’s stock price is $2.64. Its current market cap is $533M with 202M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.64 | $2.82 | $2.51 - $4.14 | $533M | 202M | 1.92M | -$0.50 |
Zhejiang Orient Gene Biotech Financials Summary
As of 30-Sep-2026, Zhejiang Orient Gene Biotech has a trailing 12-month revenue of $144M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 305,483 | 360,082 | 402,919 | 309,639 |
| Revenue | 144,080 | 131,739 | 115,382 | 115,925 |
| EBITDA | (100,464) | (63,724) | (77,024) | (60,536) |
| Net Income | (95,502) | (79,763) | (73,727) | (56,197) |
| Total Assets | 1,014,706 | 1,020,330 | 1,108,831 | 1,269,073 |
| Total Debt | 71,260 | 46,588 | 66,953 | 85,819 |
Zhejiang Orient Gene Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zhejiang Orient Gene Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zhejiang Orient Gene Biotech Patents
Zhejiang Orient Gene Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4714545-A1 | Device for testing analyte in sample | Pending | 23-Sep-2024 | ||
| EP-4715383-A1 | Test strip for testing analyte in sample | Pending | 23-Sep-2024 | ||
| AU-2024216410-A1 | Dry chemical device and method for testing analyte in urine sample or property of urine sample | Inactive | 20-Aug-2024 | ||
| EP-4700388-A1 | Dry chemical device and method for testing analyte in urine sample or property of urine sample | Pending | 20-Aug-2024 | ||
| US-20260056188-A1 | Dry chemical device and method for testing analyte in urine sample or property of urine sample | Pending | 20-Aug-2024 | G01N21/78 |
Zhejiang Orient Gene Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zhejiang Orient Gene Biotech Investments & Acquisitions (5)
Zhejiang Orient Gene Biotech’s most recent deal was a Corporate with ZX Bio. The deal was made on 09-Jun-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ZX Bio | 09-Jun-2022 | Corporate | Biotechnology | ||
| Omega Diagnostics (Diagnostic Test Kit Manufacturing Business and Facility in Alva, Scotland) | 07-Mar-2022 | Merger/Acquisition | Diagnostic Equipment | ||
| Jinlu Bio | 11-Oct-2021 | Merger/Acquisition | Diagnostic Equipment | ||
| Beijing Shouyi | 15-Aug-2021 | Merger/Acquisition | Diagnostic Equipment | ||
| Healgen Scientific | 26-Jun-2019 | Merger/Acquisition | Other Devices and Supplies |
Zhejiang Orient Gene Biotech ESG
Risk Overview
Risk Rating
Updated January, 31, 2024
28.97 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Healthcare
Industry
of 581
Rank
Percentile
Medical Devices
Subindustry
of 199
Rank
Percentile
Zhejiang Orient Gene Biotech Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Jinlu Bio | Shaoxing, China | 2015 | |
| Healgen Scientific | Houston, TX | 2007 | |
| Accubio | 2004 | ||
| Beijing Shouyi | Beijing, China | 1998 |
Zhejiang Orient Gene Biotech FAQs
-
When was Zhejiang Orient Gene Biotech founded?
Zhejiang Orient Gene Biotech was founded in 2005.
-
Where is Zhejiang Orient Gene Biotech headquartered?
Zhejiang Orient Gene Biotech is headquartered in Huzhou, China.
-
What is the size of Zhejiang Orient Gene Biotech?
Zhejiang Orient Gene Biotech has 2,283 total employees.
-
What industry is Zhejiang Orient Gene Biotech in?
Zhejiang Orient Gene Biotech’s primary industry is Diagnostic Equipment.
-
Is Zhejiang Orient Gene Biotech a private or public company?
Zhejiang Orient Gene Biotech is a Public company.
-
What is Zhejiang Orient Gene Biotech’s stock symbol?
The ticker symbol for Zhejiang Orient Gene Biotech is 688298.
-
What is the current stock price of Zhejiang Orient Gene Biotech?
As of 13-Nov-2026 the stock price of Zhejiang Orient Gene Biotech is $2.64.
-
What is the current market cap of Zhejiang Orient Gene Biotech?
The current market capitalization of Zhejiang Orient Gene Biotech is $533M.
-
What is Zhejiang Orient Gene Biotech’s current revenue?
The trailing twelve month revenue for Zhejiang Orient Gene Biotech is $144M.
-
What is Zhejiang Orient Gene Biotech’s annual earnings per share (EPS)?
Zhejiang Orient Gene Biotech’s EPS for 12 months was -$0.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
